Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19
The Pharma Data
NOVEMBER 9, 2020
Lilly’s chief scientific officer and president of Lilly Research Laboratories. Bamlanivimab remains an investigational drug and has not been approved under a Biologics License Application (BLA). Lilly is in discussions with global regulators to make bamlanivimab available around the world.
Let's personalize your content